Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ferrous fumarate + docusate sodium is a combination oral medication primarily indicated for the treatment and prevention of iron-deficiency anemia. It consists of ferrous fumarate, an iron salt that provides approximately 33% elemental iron by weight necessary for hemoglobin synthesis and erythropoiesis, and docusate sodium, a surfactant laxative that acts as a stool softener. The inclusion of docusate sodium is intended to mitigate the common side effect of constipation associated with oral iron supplementation by facilitating the penetration of water and fats into the stool. This combination is available in various formulations, including extended-release tablets and capsules, and is accessible both over-the-counter and by prescription in the United States.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferrous fumarate + docusate sodium.